Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Epidemiology and Disease Pathophysiology:
Other Anaemias
In this webcast, Dr. Ali Taher will review the aetiology, pathogenesis, clinical features, and diagnosis of rare anaemias, including Diamond Blackfan anaemia, Fanconi’s anaemia, congenital dyserythropoietic anaemia, and sideroblastic anaemia. As transfusion therapy is often used in the treatment of rare anaemias, the development and management of iron overload will also be discussed.
|
|
Faculty
|
|
|
Ali T. Taher, MD
Professor
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the epidemiology and disease pathophysiology of rare anaemias, including Diamond Blackfan anaemia, Fanconi’s anaemia, congenital dyserythropoietic anaemia and sideroblastic anaemia and recognize that patients with these disease states may be affected by factors that contribute to the development of iron overload.
- Describe the various treatment strategies available for rare anaemias such as Diamond Blackfan anaemia, Fanconi’s anaemia, congenital dyserythropoietic anaemia and sideroblastic anaemia in order to customize treatment and improve patient outcomes.
|
Disclosure Information
Ali T. Taher, MD, is on the speakers bureau of and on the advisory board for Novartis Pharmaceuticals Corporation. Prof. Taher has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
